Contact the Editorial Desk

Editorial correspondence

Peptides Long Island welcomes correspondence on the research record: a citation quoted inaccurately, a trial that has published new results, a regulatory update, or a peer-reviewed study on MOTS-c, retatrutide, or semaglutide that should be added to the references page. This class of correction is the most useful message this guide receives.

The most actionable submissions specify the page in question, the exact passage being challenged, and a supporting reference — a DOI or PubMed identifier where possible — so a proposed change can be verified before it's acted on.

Editorial mailbox: editors@peptideslongisland.com

What this guide cannot do

To spare you a wasted message: this desk keeps the literature, it does not practice medicine. It cannot tell you whether to use any peptide named here, cannot put a number or a schedule on a personal regimen, cannot judge whether a study's finding transfers to your particular circumstances, and cannot point you toward a place to buy anything. Semaglutide is dispensed only by prescription through licensed providers; retatrutide is confined to registered clinical trials; MOTS-c is a laboratory research chemical, not a human therapeutic. For a medical question, a licensed clinician is the right correspondent. Replies here are read as time allows and are not promised.